HERMOD
Exploring a new treatment aimed at slowing the progression of early-stage Parkinson’s disease
Parkinson’s disease is a progressive neurological condition that affects movement and can lead to increasing disability over time. While current treatments can help manage symptoms, there are currently no approved therapies that can slow or stop the underlying disease process. This study is investigating HER-096, an experimental treatment designed to protect nerve cells and potentially slow the progression of Parkinson’s disease. HER-096 is based on a naturally occurring protein that supports the health and survival of brain cells and has been developed to reach the brain through a simple, non-invasive treatment approach. Researchers will evaluate the safety and effectiveness of HER-096 in people with early-stage Parkinson’s disease. The study will also use innovative digital technologies, including continuous monitoring of movement symptoms, to better understand how the treatment may affect disease progression in everyday life. The findings from this research may contribute to the development of new disease-modifying therapies that target the underlying causes of Parkinson’s disease and help improve long-term outcomes for people living with the condition.
About the study
Locations
L-1210 Luxembourg
Contact
Ready to take part?
Our team is available to answer all your questions before you decide.
Who can participate?
Eligible participants
People with a recent Parkinson’s disease diagnosis (not older than 2 years) might qualify for the study. For more exact details, please contact the study team, which will review each case individually to determine eligibility
What are the possible benefits of taking part?
Taking part in the Hermod study may or may not provide a direct benefit to you. Researchers hope that the investigational treatment may help delay or prevent disease progression in people with Parkinson’s disease.
As a participant, you will also receive regular clinical assessments and close monitoring by the study team throughout the trial.
By taking part, you will contribute to research that is expected to contribute to improved clinical assessment methods, biomarker development and a deeper understanding of disease progression, which might translate scientific discoveries into potential benefits for patients, healthcare systems and society.
What are the possible risks?
As with any clinical trial, participation involves some risks.
The investigational medicine, HER-096, has already been studied in healthy volunteers and people with Parkinson’s disease. The most common side effects reported were subcutaneous injection-related reactions,. No other side-effects were so far reported.
Some study procedures may also involve minor risks:
- Blood sampling may cause temporary pain, bruising, dizziness, or, very rarely, infection.
- Lumbar puncture (optional) may cause temporary headaches or pain at the puncture site. More serious complications, such as infection or bleeding, are uncommon. The study team will carefully assess whether this procedure is safe for you before it is performed.
The study team will monitor your health closely throughout the trial and explain all potential risks before you decide whether to participate.
What will participants do?
01.
Attend a screening visit
The study team will assess whether you are eligible to take part.
02.
Be randomly assigned to a treatment group
You will receive either the investigational treatment (HER-096) or a placebo. Neither you nor the study team will know which treatment you receive during the study.
03.
Attend biweekly study visits
Visits will take place over approximately 1 year, either in hospital or at home. At each visit, you will receive your treatment as a subcutaneous injection. Most visits will last around 2 hours.
04.
Complete comprehensive clinical assessments
These will be carried out using a sensitive digital monitoring tool.
05.
Provide biological samples (optional)
These may include blood, urine, and cerebrospinal fluid (CSF) samples to monitor your health and support the study analyses.
Contact & location
Luxembourg Research Clinic (LRC)
6, Rue Nicolas-Ernest Barblé,
L-1210 Luxembourg
Study team
Prof. Dr Rejko Krüger
Coordinator, National Centre for Excellence in Research on Parkinson’s disease (NCER-PD); Director of Neurology, Luxembourg Research Clinic (LRC), Luxembourg Institute of Health (LIH); Neurologist and Medical coordinator, Réseau de Compétences Maladies Neurodégénératives, Centre Hospitalier de Luxembourg (CHL); Professor for Clinical and Experimental Neuroscience, University of Luxembourg (UL)
Centre Hospitalier de Luxembourg (CHL)Participating institutions
HERMOD is a collaboration between clinical and research partners from Sweden, Finland, Luxembourg and the Netherlands, sponsored by Herantis Pharma Plc. (Finland). Participating institutions in Luxembourg include:
Funded by
The European Union through the Horizon Europe funding programme
The European Innovation Council (EIC) Fund
Want to learn more about the study?
Visit the website for full study details, scientific publications and research background.
Ready to take part?
Our team is available to answer all your questions before you decide.
Related news & updates
Small country, significant capacity
Luxembourg may be one of Europe’s smallest countries, but the Luxembourg Research Clinic demonstrates how its highly connected national network…
Landmark agreement ensures sustainability of Luxembourg Parkinson’s programme
Three leading researchers have joined the LRC's scientific committee, bringing expertise in immunology, rare diseases, and translational genomics from institutions…
Related events
Clinical Research Luxembourg Conference
Why does clinical research matter today in Luxembourg? Clinical research plays a vital role in improving patient care, driving medical…